Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BeyoND: ND0612 Safety Study in Advanced PD
NCT02726386Phase 2Active, not recruiting
- Sponsor
- NeuroDerm Ltd.
- Start
- May 2016
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, open-label trial of levodopa and carbidopa in Parkinson's disease (PD) (2 arms), sponsored by NeuroDerm Ltd. Primary endpoints: Adverse Events (Long-term Safety) at 12 months and Percentages of Subjects Who Complete the 12-month Treatment Period or Discontinue Due to AE. Started May 2016; status: active, not recruiting.
02
Drugs
levodopacarbidopa
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02726386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02726386.